United Therapeutics Corporation (UTHR) Operating income 2016–2025
United Therapeutics Corporation (UTHR) annual operating income history from SEC filings — each fiscal year as reported.
$1.5BFY2025 · since FY2016: $1.1B → $1.5B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $1.5B | +8.4% |
| FY2024 | $1.4B | +16.2% |
| FY2023 | $1.2B | +20.9% |
| FY2022 | $979.7M | +76.2% |
| FY2021 | $555.9M | -6.4% |
| FY2020 | $593.6M | +416.4% |
| FY2019 | -$187.6M | -123.3% |
| FY2018 | $805.4M | -1.2% |
| FY2017 | $814.9M | -23.2% |
| FY2016 | $1.1B | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More UTHR financial trends
UTHR RevenueUTHR Net incomeUTHR Net marginUTHR Gross profitUTHR Gross marginUTHR Operating marginUTHR Operating cash flowUTHR Free cash flowUTHR Capital expendituresUTHR Return on equityUTHR Stock buybacksUTHR Dividends paidUTHR Total assetsUTHR Total liabilitiesUTHR Shareholders’ equityUTHR overview →